JCAD | The Journal of Clinical and Aesthetic Dermatology
Menu
© 2020 JCAD | The Journal of Clinical and Aesthetic Dermatology. All rights reserved.
Menu
VOL. 12, NO. 6 • JUNE 2019 Dear Colleagues: Welcome to the June 2019 issue of The Journal of Clinical and Aesthetic Dermatology (JCAD). In this issue, we are pleased to present the article “Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS),” by Del Rosso, Tanghetti, Webster, Stein Gold,
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. An increasing number of studies have demonstrated the efficacy of tofacitinib in treatment of alopecia areata (AA).1–6 Treatment duration in these studies
J Clin Aesthet Dermatol. 2019;12(6):17–24 by James Q. Del Rosso, DO, FAOCD, FAAD; Emil Tanghetti, MD, FAAD; Guy Webster, MD, PhD, FAAD; Linda Stein Gold, MD, FAAD; Diane Thiboutot, MD, FAAD; and Richard L. Gallo, MD, PhD, FAAD Dr. Del Rosso is Adjunct Clinical Professor of Dermatology at Touro University, Nevada in Henderson, Nevada; and
J Clin Aesthet Dermatol. 2019;12(6):27–28 by Brooke Vasicek, MD; William Adams, PhD; Laryn Steadman, BFA; Jeave Reserva, MD; and James Swan, MD Drs. Vasicek, Reserva, and Swan are with the Division of Dermatology at the Loyola University Medical Center in Hines, Illinois. Dr. Adams is with the Biostatistics Core, Health Sciences Division at the Loyola University
J Clin Aesthet Dermatol. 2019;12(6):30–41 by James Q. Del Rosso, DO; Theodore Rosen, MD; Dimitry Palceski, DO; and Maria Jose Rueda, MD Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada. Dr. Rosen is with Baylor College of Medicine in Houston, Texas. Dr. Palceski is with the Reflections Dermatology & Center